New Delhi: Orchid Pharma On Thursday, it said it has received approval from the DCGI to manufacture and market the antibiotic drug. Complicated urinary tract infection. The Drugs Controller General of India (DCGI) has approved its manufacturing and marketing in finished dosage form. Cefepime And Enmetazobactam It can be used as a dry powder injection, the pharmaceutical company said in a statement.

This formulation is indicated for the treatment of uncomplicated urinary tract infections, including acute pyelonephritis, hospital-acquired pneumonia These include ventilator-associated pneumonia (VAP) and bacteraemia.

Orchid Pharma said the DCGI has also granted approval for the manufacture and marketing of Enmetazobactam, an active pharmaceutical ingredient, a new chemical substance invented by it.

Manish Dhanuka, Managing Director, Orchid Pharma, said, “The approval of Enmetazobactam in India is personally gratifying, as being an Indian company, we wanted to expand access to advanced and affordable treatment options for patients in India.”

The company is expecting successful launch and distribution of Enmetazobactam and its combination with Cefepime to improve the quality of the product. Treatment scenarios The pharmaceutical company said that this medicine is effective for serious infections in the country.

Anti-microbial resistance (AMR) has been declared a silent pandemic by the UN and WHO and contributed to nearly 5 million deaths in 2019.

In addition to death and disability, AMR also has significant economic costs, as the World Bank estimates that it could result in US$1 trillion in additional health care costs by 2050, and US$1 trillion to US$3.4 trillion in gross domestic product (GDP) losses per year by 2030.